Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
ID: 338829Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338829

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)" aimed at supporting exploratory research for innovative technologies in biomedical research. This initiative encourages high-risk, high-reward projects that focus on developing broad-use technologies, such as laboratory instruments or algorithms, without established feasibility, thereby fostering advancements relevant to the missions of participating NIH Institutes, including the National Institute of General Medical Sciences, the National Institute on Aging, and the National Cancer Institute. Eligible applicants may receive up to $275,000 in direct costs over a two-year period, with applications evaluated based on significance, innovation, approach, and applicant expertise; however, projects that include proof of concept data will be deemed non-responsive. Interested parties should note that the application deadline is May 7, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-126.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is offering a funding opportunity (R21 - Clinical Trial Not Allowed) for exploratory research to develop innovative technologies in biomedical research. This initiative, focused on high-risk, high-reward studies, seeks projects that advance understanding and tools relevant to the missions of participating NIH Institutes, specifically the National Institute of General Medical Sciences (NIGMS), the National Institute on Aging (NIA), and the National Cancer Institute (NCI). Eligible applicants can propose projects that must not have established feasibility, focusing instead on developing broad-use technologies, such as laboratory instruments or algorithms, for various biomedical research applications. The funding amounts to a maximum of $275,000 in direct costs over two years, with specific submission deadlines and registration requirements highlighted. Applications will be evaluated based on significance, innovation, approach, and the expertise of the applicants. Notably, projects focusing on specific biological questions or that include any proof of concept data will be deemed non-responsive. This funding represents a strategic effort to foster early-stage technology development that facilitates biomedical advancements and innovation.
    Similar Opportunities
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for preclinical proof of concept studies targeting rare diseases under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established preclinical models for therapeutic agents, including small molecules and biologics, with the goal of advancing projects toward Investigational New Drug (IND) applications. The funding is particularly significant as it addresses the unmet medical needs of approximately 30 million individuals in the U.S. affected by rare diseases, enhancing the likelihood of progressing novel therapies to clinical trials. The total funding available is up to $1,200,000 for FY26, with a maximum budget of $275,000 per two-year project. Interested applicants must submit their letters of intent by May 1, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)" aimed at advancing research in computational genomics, bioinformatics, and data visualization methodologies that enhance genomic science and its application to human health. This initiative seeks innovative projects that develop novel analytical tools and methodologies, with a budget limit of $275,000 for a two-year project period, focusing on scalable solutions applicable across various diseases and biological systems. The funding is particularly targeted at underrepresented entities in genomic research, including higher education institutions, nonprofits, and governmental bodies, reflecting NIH's commitment to fostering collaborative research in this critical field. Interested applicants should note that key submission dates begin on January 16, 2025, with a final expiration date of September 8, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Basic Experimental Studies with Humans Required) to support innovative research projects that involve basic experimental studies with human participants. This funding opportunity aims to foster groundbreaking research strategies that can lead to significant advancements in biomedical, behavioral, or clinical research, particularly in understanding fundamental phenomena without immediate application in mind. Grants may be awarded for a total project period of up to two years, with budgets capped at $275,000, and applications are encouraged from a diverse range of eligible applicants, including historically black colleges and universities, faith-based organizations, and other institutions. Interested parties should note that the application deadline is January 7, 2028, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)" aimed at supporting clinical projects that enhance readiness for clinical trials in rare diseases. This initiative seeks applications that focus on developing and testing biomarkers and clinical outcome measures, as well as defining the characteristics of rare diseases to facilitate the design of future clinical trials. The program is particularly important for addressing the needs of rare diseases affecting fewer than 200,000 individuals in the U.S., with a maximum budget of $275,000 for direct costs over a project period of up to two years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for July 20, 2028.